Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02451839
Registration number
NCT02451839
Ethics application status
Date submitted
20/05/2015
Date registered
22/05/2015
Date last updated
19/06/2019
Titles & IDs
Public title
An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
Query!
Scientific title
An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
Query!
Secondary ID [1]
0
0
P15-345
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
VITALITY
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease
0
0
Query!
Rheumatoid Arthritis
0
0
Query!
Psoriasis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Crohn's Disease - Participants with Crohn's disease. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
Rheumatoid Arthritis - Participants with rheumatoid arthritis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
Psoriasis - Participants with psoriasis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in WHODAS 2.0 Response Score at Month 6 Across All Indications
Query!
Assessment method [1]
0
0
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation. Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed. Scores can range from 0 to 48. Persons scoring 10 to 48 are likely to have clinically significant disability.
Query!
Timepoint [1]
0
0
Baseline, Month 6
Query!
Secondary outcome [1]
0
0
Change From Baseline in WHODAS 2.0 Response Score at Month 2 Across All Indications
Query!
Assessment method [1]
0
0
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation. Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed. Scores can range from 0 to 48. Persons scoring 10 to 48 are likely to have clinically significant disability.
Query!
Timepoint [1]
0
0
Baseline, Month 2
Query!
Secondary outcome [2]
0
0
Change From Baseline in WHODAS 2.0 Response Score at Month 4 Across All Indications
Query!
Assessment method [2]
0
0
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation. Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed. Scores can range from 0 to 48. Persons scoring 10 to 48 are likely to have clinically significant disability.
Query!
Timepoint [2]
0
0
Baseline, Month 4
Query!
Secondary outcome [3]
0
0
Change From Baseline in WHODAS 2.0 Response Score at Month 6 in Participants With Crohn's Disease
Query!
Assessment method [3]
0
0
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation. Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed. Scores can range from 0 to 48. Persons scoring 10 to 48 are likely to have clinically significant disability.
Query!
Timepoint [3]
0
0
Baseline, Month 6
Query!
Secondary outcome [4]
0
0
Change From Baseline in WHODAS 2.0 Response Score at Month 6 In Participants With Psoriasis
Query!
Assessment method [4]
0
0
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation. Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed. Scores can range from 0 to 48. Persons scoring 10 to 48 are likely to have clinically significant disability.
Query!
Timepoint [4]
0
0
Baseline, Month 6
Query!
Secondary outcome [5]
0
0
Change From Baseline in WHODAS 2.0 Response Score at Month 6 in Participants With Rheumatoid Arthritis
Query!
Assessment method [5]
0
0
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation. Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed. Scores can range from 0 to 48. Persons scoring 10 to 48 are likely to have clinically significant disability.
Query!
Timepoint [5]
0
0
Baseline, Month 6
Query!
Secondary outcome [6]
0
0
Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Absenteeism
Query!
Assessment method [6]
0
0
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities. The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. The questionnaire specifies responses for the previous 7 days.
Query!
Timepoint [6]
0
0
Baseline, Month 6
Query!
Secondary outcome [7]
0
0
Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Presenteeism
Query!
Assessment method [7]
0
0
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities. The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. The questionnaire specifies responses for the previous 7 days.
Query!
Timepoint [7]
0
0
Baseline, Month 6
Query!
Secondary outcome [8]
0
0
Change From Baseline in WPAI:GH 2.0 Score at Month 6 Across All Indications: Work Productivity Loss
Query!
Assessment method [8]
0
0
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities. The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. The questionnaire specifies responses for the previous 7 days.
Query!
Timepoint [8]
0
0
Baseline, Month 6
Query!
Secondary outcome [9]
0
0
Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Activity Impairment
Query!
Assessment method [9]
0
0
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities. The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. The questionnaire specifies responses for the previous 7 days.
Query!
Timepoint [9]
0
0
Baseline, Month 6
Query!
Secondary outcome [10]
0
0
Change From Baseline in K10 at Month 6 Across All Indications
Query!
Assessment method [10]
0
0
The K10 is intended to yield a global measure of distress based on a questionnaire about anxiety and depressive symptoms that a person has experienced in the most recent 4 week period. The K10 scale involves 10 questions about emotional states each with a 5-level response scale. Each item is scored from 1=none of the time to 5=all of the time. Scores of the 10 items are then summed, yielding a minimum score of 10 and a maximum score of 50. Low scores indicate low levels of psychological distress and high scores indicate high levels of psychological distress.
Query!
Timepoint [10]
0
0
Baseline, Month 6
Query!
Secondary outcome [11]
0
0
Change From Baseline in Flourishing Scale at Month 6 Across All Indications
Query!
Assessment method [11]
0
0
The Flourishing Scale is a brief 8-item summary measure of the respondent's self-perceived success in important areas such as relationships, self-esteem, purpose, and optimism. The scale provides a single psychological well-being score. Participants are asked to respond to 8 statements using a scale of 1 (strongly disagree) and 7 (strongly agree) for each item. The possible range of scores is from 8 (lowest possible) to 56 (highest possible), with higher scores representing more psychological resources and strengths.
Query!
Timepoint [11]
0
0
Baseline, Month 6
Query!
Secondary outcome [12]
0
0
Change From Baseline in Subjective Vitality Scale at Month 6 Across All Indications
Query!
Assessment method [12]
0
0
The Subjective Vitality Scale assesses the state of feeling alive and alert to having energy available to the self. Patients respond to eight prompts, with a response ranging from 1=strongly disagree to 7=strongly agree. The sum of the scores is calculated with a higher score indicating a better condition. The total score ranges from 8 to 56 with a higher score indicating a better condition.
Query!
Timepoint [12]
0
0
Baseline, Month 6
Query!
Secondary outcome [13]
0
0
Change From Baseline in HAQ-DI Score at Month 6 in Participants With Rheumatoid Arthritis
Query!
Assessment method [13]
0
0
HAQ-DI measures functional status in rheumatic diseases. It has 20 items, and asks patients to report the degree of difficulty faced in several areas of their life including: dressing and grooming, arising, eating, walking, hygiene, reach, grip, activities based on the previous week on a scale from 0 (without any difficulty) to 3 (cannot be done at all). It also asks the participant to rate their pain and health in the previous week. Scores on each task are summed and averaged to provide an overall score ranging from 0 (no disability) to 3 (very severe, high-dependency disability).
Query!
Timepoint [13]
0
0
Baseline, Month 6
Query!
Secondary outcome [14]
0
0
Change From Baseline in SIBDQ Score at Month 6 in Participants With Crohn's Disease
Query!
Assessment method [14]
0
0
The SIBDQ is a simple validated, 10-item questionnaire designed to find out how the patient has been feeling in the previous 2 weeks. QoL is measured in 4 domains: bowel symptoms, emotional health, systemic systems and social function. Participants respond to questions ranging from 1=all of the time to 7=none of the time. Scores are added together, with higher scores indicating a better health-related QoL. Total scores range from 10 (poor QoL) to 70 (good QoL).
Query!
Timepoint [14]
0
0
Baseline, Month 6
Query!
Secondary outcome [15]
0
0
Change From Baseline in DLQI Score at Month 6 in Participants With Psoriasis
Query!
Assessment method [15]
0
0
The DLQI measures 10 items covering the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, to determine how much the patients skin problem affected their life in the past week. Participants respond to the questions with 'very much,' 'a lot,' 'a little,' or 'not at all.' The scores are added together, and the impact on QoL is banded as follows: 0-1=no effect on participant's life; 2-5=small effect; 6-10=moderate effect; 11-20=very large effect; 21-30=extremely large effect.
Query!
Timepoint [15]
0
0
Baseline, Month 6
Query!
Secondary outcome [16]
0
0
Number of Participants Remaining on Treatment at Month 6
Query!
Assessment method [16]
0
0
The number of participants at 6 months who remained on adalimumab, having satisfied the requirements for application for renewal of subsidy by special authority.
Query!
Timepoint [16]
0
0
Month 6
Query!
Eligibility
Key inclusion criteria
- Patients with a diagnosis of rheumatoid arthritis, Crohn's disease or psoriasis who
have made a decision with their physician to commence treatment with adalimumab in
accordance with routine medical practice and with the approved adalimumab New Zealand
Datasheet.
- Patients who have been evaluated for tuberculosis risk factors/exposure for
active/latent tuberculosis infection (per local requirements and according to the
approved adalimumab New Zealand Datasheet).
- Adult subjects, 18-75 years old, who have voluntarily signed and dated an informed
consent form prior to any study-specific procedures.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Previous treatment with adalimumab.
- Previous treatment with any biologic.
- Severe infection including sepsis, active tuberculosis or opportunistic infection.
- Moderate to severe heart failure (New York Heart Association Class II/III).
- Concurrent administration with anakinra.
- Hypersensitivity to adalimumab or its excipients.
- Any condition that in the opinion of the investigator would compromise the subject's
well-being or ability to perform the study requirements.
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
6/07/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/12/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
168
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
For public health purposes disability is becoming increasingly important as an outcome
measure. Despite this, there are few data on the effectiveness of adalimumab on disability
outcomes in patients with immune-mediated inflammatory diseases (IMIDs), particularly in the
Phase IV setting. There are even less data available in New Zealand, which did not have the
opportunity to participate to a major extent in large, multinational, Phase III pivotal
studies of adalimumab in IMIDs.
The World Health Organisation Disability Assessment Schedule (WHODAS) 2.0 is a simple,
validated, free and easy-to-use generic assessment instrument for health and disability. It
is applicable across cultures, in all adult populations. It is a responsive measure that can
show what difference a treatment makes.
Results from study of effect of adalimumab on WHODAS scores and other patient-reported
outcomes (PROs) of work activity and well-being will be of interest to a variety of
stakeholders in the healthcare system including patients, healthcare practitioners and
payers.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02451839
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
AbbVie Inc.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02451839
Download to PDF